top of page

Mwandishi

Mhariri:

Imeboreshwa:

< Orodha kuu

ULY CLINIC

ULY CLINIC

Jumanne, 14 Julai 2026, 23:07:34 UTC

Emphysema management

Emphysema

Emphysema is a destructive process involving the gas-exchanging air spaces of the lungs that results in perforations, obliteration of airspace walls, and coalescence of small distinct airspaces into much larger ones, leading to enlargement of the gas-exchanging units of the lungs.

These changes cause loss of elastic recoil of the lungs and abnormal gas exchange.



Clinical presentation

  • Shortness of breath

  • Cough, sometimes caused by the production of mucus

  • Wheezing

  • Slow and prolonged expiration

  • Chest wall hyperinflation

  • Limited diaphragmatic motion on auscultation

  • Distant breath sounds and heart sounds

  • Coarse early inspiratory crackles

  • Use of accessory muscles

  • Pursed-lip breathing

  • Signs of cor pulmonale:

    • Raised JVP

    • Peripheral oedema

    • Hepatomegaly

    • Other features of right heart failure

  • Cyanosis

  • Asterixis


Investigations

  • Haematocrit:

    • Men >52%

    • Women >47%

OR

  • FBP (look at haematocrit)

  • ABG (look for elevated bicarbonate/metabolic alkalosis)

  • CXR

  • Sputum culture and microbial sensitivity

  • Pulmonary function tests

  • Six-minute walk test

  • CT scan of the chest/HRCT (for evaluation for lung volume reduction surgery)


Non-pharmacological treatment

  • Stop smoking.

  • Give oxygen after evaluation.


Pharmacological treatment

Inhaled bronchodilators relax and open the airways.

They may be:


Short-acting bronchodilators

  • Albuterol

  • Ipratropium


Long-acting bronchodilators

  • Salmeterol

  • Tiotropium

These medicines may be available as inhalers ("puffers") or as solutions for nebulization.

A nebulizer machine aerosolizes the bronchodilator solution, which is then breathed through a tube.

For more details, refer to treatment in Section 9.2 above.


Table: COPD staging and recommended therapies

GOLD stage (FEV1)

Exacerbations per year

Mild symptoms

Moderate/Severe symptoms

Stage I (≥80%)

≤2

Group A: Bronchodilator (SABA PRN)

Group B: LAMA or LABA

Stage II (50–79%)

≤2

Group A: Bronchodilator (SABA PRN)

Group B: LAMA or LABA

Stage III (30–49%)

≥2

Group C: LAMA + LABA

Group D: LAMA or LAMA + LABA or ICS + LABA

Stage IV (<30%)

≥2

Group C: LAMA + LABA

Group D: LAMA or LAMA + LABA or ICS + LABA


Abbreviations

  • FEV1 = Forced Expiratory Volume in 1 second

  • SABA = Short-Acting Beta-Agonist

  • LABA = Long-Acting Beta-Agonist

  • LAMA = Long-Acting Muscarinic Antagonist

  • ICS = Inhaled Corticosteroid

  • HRCT = High-Resolution Computed Tomography

  • ABG = Arterial Blood Gas

  • CXR = Chest X-ray

  • FBP = Full Blood Picture

  • JVP = Jugular Venous Pressure

Imeandikwa:

Jumatatu, 22 Juni 2026, 11:22:51 UTC

References:

bottom of page